Onychomysosis
☆ AI Dermatology — Free Service
I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
He matikuku i pangia e Onychomycosis
Ko te waewae o te tangata kua pāngia e te whāwhā harore mō te tekau wiki i roto i te akoranga rongoā ā-waha o terbinafine. Tuhia te rōpū o te tipu o ngā whāwhā hauora i muri i ngā tōenga o ngā whāwhā kua pāngia.
relevance score : -100.0%
ReferencesKo ngā pūnaha anti‑fungal te maimoatanga tino whai hua. Ko ngā tātari‑meta e whakaatu ana i ngā reiti whakaora mō te mate mycotic e whai ake nei: terbinafine = 76 %, itraconazole with pulse dosing = 63 %, itraconazole with continuous dosing = 59 %, fluconazole = 48 %. Ko te whakaheke i ngā whā o te rongoā ka piki ake ngā reiti rongoā. He iti ake te whai hua o te rongoā o runga me te ciclopirox; he reiti rahunga neke atu i te 60 %.
Systemic antifungals are the most effective treatment. Meta-analyses shows mycotic cure rates as follows: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48%. Concomitant nail debridement further increases cure rates. Topical therapy with ciclopirox is less effective; it has a failure rate exceeding 60%.
Systemic antifungals are the most effective treatment. Meta-analyses shows mycotic cure rates as follows: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48%. Concomitant nail debridement further increases cure rates. Topical therapy with ciclopirox is less effective; it has a failure rate exceeding 60%.
Ko te Onychomycosis he mate harore e pā ana ki ngā whā. Ko te dermatophytes te take, ka kīia ko te tinea unguium. Kei roto i te Onychomycosis ngā momo kōroro nā te dermatophytes, te rewena, me te koriri. Ko te raruraru maikuku, ehara i te mate harore, ka kīia ko te nail dystrophy. Ahakoa ka pā ki ngā maikuku me ngā matikuku, he nui ake te onychomycosis maikuku. Ka matapakihia e tēnei tuhinga ngā momo āhuatanga o te onychomycosis maikuku, pērā i tōna pānga, ngā momo haumanu, ngā wāhanga, te tātai, me te maimoatanga. Ahakoa ehara i te mea whakamate, ka taea e te onychomycosis te arahi ki ngā raru nui pērā i te cellulitis, te sepsis, te mate wheua, te kino o te kiko, me te mate maikuku.
Onychomycosis is a fungal infection of the nail unit. When dermatophytes cause onychomycosis, this condition is called tinea unguium. The term onychomycosis encompasses the dermatophytes, yeasts, and saprophytic mold infections. An abnormal nail not caused by a fungal infection is a dystrophic nail. Onychomycosis can infect both fingernails and toenails, but onychomycosis of the toenail is much more prevalent. Discussed in detail in this activity are all evolving facets of the topic, including disease burden, clinical types, staging, diagnosis, and management of toenail onychomycosis. While non-life-threatening, onychomycosis can lead to severe complications such as cellulitis, sepsis, osteomyelitis, tissue damage, and nail loss.
Onychomycosis is a fungal infection of the nail unit. When dermatophytes cause onychomycosis, this condition is called tinea unguium. The term onychomycosis encompasses the dermatophytes, yeasts, and saprophytic mold infections. An abnormal nail not caused by a fungal infection is a dystrophic nail. Onychomycosis can infect both fingernails and toenails, but onychomycosis of the toenail is much more prevalent. Discussed in detail in this activity are all evolving facets of the topic, including disease burden, clinical types, staging, diagnosis, and management of toenail onychomycosis. While non-life-threatening, onychomycosis can lead to severe complications such as cellulitis, sepsis, osteomyelitis, tissue damage, and nail loss.
Ko te Terbinafine he rongoā hei patu i ngā māte harore mā te aukati i te squalene epoxidase. He whai hua ki te nuinga o ngā momo harore kiri, ka whakaaetia mō te rongoā i te harore maikuku ina tangohia mā te waha. Ahakoa ko te nuinga o ngā pānga o te taha pērā i te māhunga me ngā take o te puku he iti noa iho, ka haere noa atu, ka rerekē ngā huringa o te reka (dysgeusia) mai i te ngawari ki te kino, i ētahi wā ka heke te taumaha. He ōngē noa ngā huringa reka tonu, engari kua kore riro.
Terbinafine is an antifungal medication that works through the inhibition of squalene epoxidase. It has activity against most dermatophytes, and it has approval for use as an oral therapy for the treatment of onychomycosis. Although most side effects are mild and self-limited, such as headache and gastrointestinal symptoms, taste disturbances (dysgeusia) can range from mild to severe, resulting in weight loss, and have rarely been reported permanent.
Terbinafine is an antifungal medication that works through the inhibition of squalene epoxidase. It has activity against most dermatophytes, and it has approval for use as an oral therapy for the treatment of onychomycosis. Although most side effects are mild and self-limited, such as headache and gastrointestinal symptoms, taste disturbances (dysgeusia) can range from mild to severe, resulting in weight loss, and have rarely been reported permanent.
Ko te Onychomycosis he mate harore e pā ana ki ngā whā. Tata ki te 90 % o ngā mate maikuku, ā, ki te 75 % o ngā mate maikuku nā te harore (Trichophyton mentagrophytes, Trichophyton rubrum). Ko ngā tohu ko te pahekētanga o ngā whā, te matotoru, te wehe mai i te moe o te whā, me te tipu nui. Ko te nuinga o ngā māimoatanga ko ngā rongoā-waha pērā i te terbinafine, itraconazole rānei, me ngā māimoatanga o runga hei whiringa mō ngā kīhē ngawari me te ngawari.
Onychomycosis is a fungal infection of the nail unit. Approximately 90% of toenail and 75% of fingernail onychomycosis are caused by dermatophytes, notably Trichophyton mentagrophytes and Trichophyton rubrum. Clinical manifestations include discoloration of the nail, subungual hyperkeratosis, onycholysis, and onychauxis. Currently, oral terbinafine is the treatment of choice, followed by oral itraconazole. In general, topical monotherapy can be considered for mild to moderate onychomycosis.
Onychomycosis is a fungal infection of the nail unit. Approximately 90% of toenail and 75% of fingernail onychomycosis are caused by dermatophytes, notably Trichophyton mentagrophytes and Trichophyton rubrum. Clinical manifestations include discoloration of the nail, subungual hyperkeratosis, onycholysis, and onychauxis. Currently, oral terbinafine is the treatment of choice, followed by oral itraconazole. In general, topical monotherapy can be considered for mild to moderate onychomycosis.
Ko te rongoā antifungal terbinafine i tētahi māngai, he tino whai hua, engari ka pā te terbinafine ki te taha o te ate.
Ka puta te onychomycosis i roto i te 10 % o te taupori pakeke, he nui ake te pā o te hunga pakeke. He maha ake ngā wā ka pā ki ngā tāne i ngā wāhine. Ko te onychomycosis te tohu mō te haurua o te māuiui whā. Ko te tikanga, ko te āhua kino o ngā matikuku ka puta mai i ngā take kē atu i te onychomycosis.
○ Māimoatanga – Rongoā OTC
He uaua ki te rongoā i te onychomycosis me ngā rongoā OTC nā te mea he uaua mō ngā rāau tāero ki te kuhu ki ngā māikuku kua matotoru.
#Ketoconazole
#Clotrimazole
#Miconazole
#Terbinafine
#Butenafine [Lotrimin]
#Tolnaftate
○ Māimoatanga
Ko te māimoatanga mō te wā roa ka hiahiatia kia tangohia anō te māikuku kua pāngia.
#Terbinafine (oral)
#Itraconazole
#Efinaconazole lacquer [Jublia]
#Ciclopirox lacquer